SABCS: Addition of Tucatinib Ups Survival in HER2 & #43; Metastatic Breast Cancer

WEDNESDAY, Dec. 11, 2019 -- Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news